UCSF Helen Diller Family Comprehensive Cancer Center
Research facility
Location:
San Francisco, CA,
United States (USA) (US)
ISNI: 0000000404349023
ROR: https://ror.org/01t8svj65
Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019)
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al.
Conference contribution
Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial (2019)
Fasching P, Quek RGW, Bhattacharyya H, Hurvitz SA, Rugo HS, Ettl J
Conference contribution
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018)
Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al.
Conference contribution
Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018)
Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al.
Conference contribution
Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018)
Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al.
Journal article
Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome (2017)
Pavel ME, Gable J, Kulke MH, Bergsland E, Anthony LB, Caplin ME, Oberg KE, et al.
Conference contribution